| Phase 12 trials |
|
Phase 1
|
NCT07156227 |
Feb 2027 → May 2029 expected |
hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma +1 |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04855656 |
Apr 2021 → Dec 2027 expected |
neoplasm |
Debiopharm International SA |
Recruiting
|
No outcome recorded
|
| Phase 1/25 trials |
|
Phase 1/2
|
NCT05566574 |
Sep 2022 → Sep 2026 expected |
metastatic malignant neoplasm |
Memorial Sloan Kettering Cancer Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05405309 |
Sep 2022 → Oct 2023 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
University of Utah |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT04972110 |
Jul 2021 → Nov 2024 |
— |
Repare Therapeutics |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT04497116 |
Jul 2020 → Jun 2025 |
neoplasm |
Repare Therapeutics |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT03337698 |
Dec 2017 → Oct 2025 |
non-small cell lung carcinoma |
Hoffmann-La Roche |
Terminated
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT05601440 |
Jun 2023 → Dec 2027 expected |
female breast carcinoma |
Canadian Cancer Trials Group |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04589845 |
Jan 2021 → Sep 2032 expected |
cancer |
Hoffmann-La Roche |
Active not recruiting
|
No outcome recorded
|